2018 FDA Tides Harvest

Danah Al Shaer; Othman Al Musaimi; Fernando Albericio; Beatriz G de la Torre

doi:10.3390/ph12020052

2018 FDA Tides Harvest

Pharmaceuticals (Basel). 2019 Apr 5;12(2):52. doi: 10.3390/ph12020052.

Authors

Danah Al Shaer^{1

2}, Othman Al Musaimi^{3

4}, Fernando Albericio^{5

6}, Beatriz G de la Torre⁷

Affiliations

¹ KRISP, School of Laboratory of Medicine and Medical Science, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa. 217078895@stuukznac.onmicrosoft.com.
² School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa. 217078895@stuukznac.onmicrosoft.com.
³ KRISP, School of Laboratory of Medicine and Medical Science, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa. 217078894@stuukznac.onmicrosoft.com.
⁴ School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa. 217078894@stuukznac.onmicrosoft.com.
⁵ School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa. albericio@ukzn.ac.za.
⁶ CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine and Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain. albericio@ukzn.ac.za.
⁷ KRISP, School of Laboratory of Medicine and Medical Science, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa. garciadelatorreb@ukzn.ac.za.

Abstract

In 2018, the United States Food and Drug Administration (FDA) approved a total of 59 new drugs, three of them (5%) are TIDES (or also, -tides), two oligonucleotides and one peptide. Herein, the three TIDES approved are analyzed in terms of medical target, mode of action, chemical structure, and economics.

Keywords: Lutathera; Onpattro; Tegsedi; dotatate; drugs; inotersen; oligonucleotides; patisiran; peptides; pharmaceutical market.

Publication types

Review

Abstract

Publication types

Grants and funding